Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning

Blood

Volumn 104, Issue 6, 2004, Pages 1616-1623

  Ho, Aloysius Y L ^a   Pagliuca, Antonio ^a   Kenyon, Michelle ^a   Parker, Jane E ^a   Mijovic, Aleksandar ^a   Devereux, Stephen ^a   Mufti, Ghulam J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGRAFT; ARTICLE; BLOOD DONOR; CANCER SURVIVAL; CHIMERA; CLINICAL PROTOCOL; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG DOSE REGIMEN; DYSPLASIA; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; MULTILINEAGE DYSPLASIA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REDUCED INTENSITY CONDITIONED REGIMEN; SCORING SYSTEM; SIBLING; VOLUNTEER;

EID: 4444283753     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-12-4207     Document Type: Article

References (61)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
2. Iwakiri R, Ohta M, Mikoshiba M, Tsutsumi H, Kumakawa T, Mori M. Prognosis of elderly patients with acute myelogenous leukemia: analysis of 126 AML cases. Intl J Hematol. 2002;75:45-50.
3. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999;94:1086-1099.
4. de Witte T, Hermans J, Vossen J, et al. Haematopoietic stem cell transplantation for patients with myelodysplastic syndromes and secondary acute myeloid leukaemias: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Brit J Haematol. 2000;110:620-630.
5. De Witte T. Stem cell transplantation for patients with myelodysplastic syndrome and secondary leukemias. Intl J Hematol. 2000;72:151-156.
6. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326-2331.
7. Deeg HJ, Appelbaum FR. Hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Leuk Res. 2000;24:653-663.
8. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002;99:75-82.
9. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071-1078.
10. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531-4536.
11. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
12. Martino R, Caballero MD, Canals C, et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol. 2001;115:653-659.
13. Jaffe E HN, Stein H, Vardiman JW. World Health Organisation classification of tumours, pathology and genetics of tumours of haematopoietic and lymphoid tissues. In: Jaffe E HN, Stein H, Vardiman JW, eds. Lyon, France: IARC Press; 2001.
14. Hurley CK, Wade JA, Oudshoorn M, et al. Histocompatibillty testing guidelines for hematopoietic stem cell transplantation using volunteer donors, report from The World Marrow Donor Association: Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Bone Marrow Transplant. 1999;24:119-121.
15. Therapy Evaluation Programme, Common Toxicity Criteria, Version 2.0. Rockville, MD: National Cancer Institute; 1999.
16. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
17. Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 1997;99:939-944.
18. Ho AY, Adams S, Shaikh H, Pagliuca A, Devereux S, Mufti GJ. Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. Bone Marrow Transplant. 2002;29:867-869.
19. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone marrow transplantation for 93 patients with myelodysplastic syndrome. Blood. 1993;82:677-681.
20. Sutton L, Leblond V, Le Maignan C, et al. Bone marrow transplantation for myelodysplastic syndrome and secondary leukemia: outcome of 86 patients. Bone Marrow Transplant. 1991;7(suppl 2):39.
21. Castro-Malaspina H, Harris RE, Gajewski J, et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood. 2002;99:1943-1951.
22. Zikos P, Van Lint MT, Frassoni F, et al. Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood. 1998;91:3503-3508.
23. Deeg HJ, Storer B, Slattery JT, et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood. 2002;100:1201-1207.
24. Deeg HJ, Shulman HM, Anderson JE, et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood. 2000;95:1188-1194.
25. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
26. Raiola AM, Van Lint MT, Lamparelli T, et al. Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. Br J Haematol. 2000;109:716-721.
27. Martino R, Caballero MD, Perez Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100:2243-2245.
28. Taussig DC, Davies AJ, Cavenagh JD, et al. Durable remissions of myelodysplastic syndrome and acute myeloid leukemia after reduced-intensity allografting. J Clin Oncol. 2003;21:3060-3065.
29. Cull GM, Haynes AP, Byrne JL, et al. Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity. Br J Haematol. 2000;108:754-760.
30. Hale G, Jacobs P, Wood L, et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transplant. 2000;26:69-76.
31. Klangsinsirikul P, Carter GI, Byrne JL, Hale G, Russell NH. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood. 2002;99:2586-2591.
32. Buggins AGS, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood. 2002:100:1715-1720.
33. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99:4357-4363.
34. Chakrabarti S, Mautner V, Osman H, et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood. 2002;100:1619-1627.
35. Chakrabarti S, Avivi I, Mackinnon S, et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: high incidence but low mortality. Br J Haematol. 2002;119:1125-1132.
36. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578-2585.
37. Yakoub-Agha I, de La Salmoniere P, Ribaud P, et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol. 2000;18:963-971.
38. Ho AYL, Kenyon M, Czepulkowski B, et al. Reduced-intensity allogeneic haematopoietic stem cell transplantation (HSCT) using fludarabine, busulphan & alemtuzumab conditioning in 63 patients with myelodysplastic syndromes (MDS) [abstract]. Br J Haematol. 2003;121(suppl 1):90.
39. Ho AYL, Kenyon M, El-Hemaidi I, Devereux S, Pagliuca A, Mufti GJ. Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. Blood. 2003;101:779-780.
40. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12:S25-S29.
41. Ratanatharathorn V, Karanes C, Uberti J, et al. Busulfan-based regimens and allogeneic bone marrow transplantation in patients with myelodysplastic syndromes. Blood. 1993;81:2194-2199.
42. Demuynck H, Verhoef GE, Zachee P, et al. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors. Bone Marrow Transplant. 1996;17:745-751.
43. Ballen KK, Gilliland OG, Guinan EC, et al. Bone marrow transplantation for therapy-related myelodysplasia: comparison with primary myelodysplasia. Bone Marrow Transplant. 1997;20:737-743.
44. Nevill TJ, Shepherd JD, Reece DE, et al. Treatment of myelodysplastic syndrome with busulfan-cyclophosphamide conditioning followed by allogeneic BMT. Bone Marrow Transplant. 1992;10:445-450.
45. Nevill TJ, Fung HC, Shepherd JD, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood. 1998;92:1910-1917.
46. Sutton L, Chastang C, Ribaud P, et al. Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Societe Francaise de Greffe de Moelle. Blood. 1996;88:358-365.
47. Runde V, de Witte T, Arnold R, et al. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome: Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21:255-261.
48. O'Donnell MR, Long GD, Parker PM, et al. Busulfan/cyclophosphamide as conditioning regimen for allogeneic bone marrow transplantation for myelodysplasia. J Clin Oncol. 1995;13:2973-2979.
49. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997-2004.
50. Parker JE, Shafi T, Pagliuca A, et al. Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. Br J Haematol. 2002;119:144-154.
51. Elmaagacli AH, Runkel K, Steckel N, et al. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase. Bone Marrow Transplant. 2001;27:809-815.
52. Barta A, Batai A, Kelemen E, et al. Immunological importance of chimerism in transplantation: new conditioning protocol in BMT and the development of chimeric state. Hum Immunol. 2000;61:101-110.
53. Nakao S, Zeng W, Yamazaki H, et al. Early establishment of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation in comparison with allogeneic bone marrow transplantation. Europ J Haematol. 1999;62:265-270.
54. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
55. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003;102:2021-2030.
56. Panse J, Heimfeld S, Guthrie KA, Storb R, Sandmaier BM. Effect of PBSC graft-composition on T-cell chimerism, rejection and outcome in nonmyeloablative HSCT: NK-cells predict for T-cell engraftment [abstract]. Blood. 2001;98:477a.
57. Fernandez-Aviles F, Urbano-Ispizua A, Aymerich M, et al. Serial quantification of lymphoid and myeloid mixed chimerism using multiplex PCR amplification of short tandem repeat-markers predicts graft rejection and relapse, respectively, after allogeneic transplantation of CD34+ selected cells from peripheral blood. Leukemia. 2003;17:613-620.
58. Theil K, Warshawsky I, Tubbs R, et al. Dynamics of T-cell (CD3+) mixed chimerism after non-myeloablative allogeneic peripheral blood stem cell transplant (PBSCT) [abstract]. Blood. 2001;98:189a.
59. Bock SH, Pihusch M, Heller T, et al. Chimerism of peripheral blood dendritic cells in patients after allogeneic hematopoietic cell transplantation [abstract]. Blood. 2001;98:188a.
60. Clark FJ, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation. 2003;75:221-225.
61. Hochberg EP, Miklos DB, Neuberg D, et al. A novel rapid single nucteotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003;101:363-369.